Protein-Based Nanoparticle Vaccines for SARS-CoV-2
The pandemic caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has upended healthcare systems and economies around the world. Rapid understanding of the structural biology and pathogenesis of SARS-CoV-2 has allowed the development of emergency use or FDA-approved vaccines an...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-12-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/24/13445 |
| _version_ | 1797503780550344704 |
|---|---|
| author | Hyo-Dong Sung Nayeon Kim Yeram Lee Eun Jung Lee |
| author_facet | Hyo-Dong Sung Nayeon Kim Yeram Lee Eun Jung Lee |
| author_sort | Hyo-Dong Sung |
| collection | DOAJ |
| description | The pandemic caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has upended healthcare systems and economies around the world. Rapid understanding of the structural biology and pathogenesis of SARS-CoV-2 has allowed the development of emergency use or FDA-approved vaccines and various candidate vaccines. Among the recently developed SARS-CoV-2 candidate vaccines, natural protein-based nanoparticles well suited for multivalent antigen presentation and enhanced immune stimulation to elicit potent humoral and cellular immune responses are currently being investigated. This mini-review presents recent innovations in protein-based nanoparticle vaccines against SARS-CoV-2. The design and strategy of displaying antigenic domains, including spike protein, receptor-binding domain (RBD), and other domains on the surface of various protein-based nanoparticles and the performance of the developed nanoparticle-based vaccines are highlighted. In the final part of this review, we summarize and discuss recent advances in clinical trials and provide an outlook on protein-based nanoparticle vaccines. |
| first_indexed | 2024-03-10T03:55:14Z |
| format | Article |
| id | doaj.art-078fa75834ef4e42b29fb37b95f08776 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T03:55:14Z |
| publishDate | 2021-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-078fa75834ef4e42b29fb37b95f087762023-11-23T08:46:27ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-12-0122241344510.3390/ijms222413445Protein-Based Nanoparticle Vaccines for SARS-CoV-2Hyo-Dong Sung0Nayeon Kim1Yeram Lee2Eun Jung Lee3Department of Chemical Engineering, School of Applied Chemical Engineering, Kyungpook National University, Daegu 41566, KoreaDepartment of Chemical Engineering, School of Applied Chemical Engineering, Kyungpook National University, Daegu 41566, KoreaDepartment of Chemical Engineering, School of Applied Chemical Engineering, Kyungpook National University, Daegu 41566, KoreaDepartment of Chemical Engineering, School of Applied Chemical Engineering, Kyungpook National University, Daegu 41566, KoreaThe pandemic caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has upended healthcare systems and economies around the world. Rapid understanding of the structural biology and pathogenesis of SARS-CoV-2 has allowed the development of emergency use or FDA-approved vaccines and various candidate vaccines. Among the recently developed SARS-CoV-2 candidate vaccines, natural protein-based nanoparticles well suited for multivalent antigen presentation and enhanced immune stimulation to elicit potent humoral and cellular immune responses are currently being investigated. This mini-review presents recent innovations in protein-based nanoparticle vaccines against SARS-CoV-2. The design and strategy of displaying antigenic domains, including spike protein, receptor-binding domain (RBD), and other domains on the surface of various protein-based nanoparticles and the performance of the developed nanoparticle-based vaccines are highlighted. In the final part of this review, we summarize and discuss recent advances in clinical trials and provide an outlook on protein-based nanoparticle vaccines.https://www.mdpi.com/1422-0067/22/24/13445SARS-CoV-2protein nanoparticlesvaccinesnanovaccinenanomedicineprotein-based nanotechnology |
| spellingShingle | Hyo-Dong Sung Nayeon Kim Yeram Lee Eun Jung Lee Protein-Based Nanoparticle Vaccines for SARS-CoV-2 International Journal of Molecular Sciences SARS-CoV-2 protein nanoparticles vaccines nanovaccine nanomedicine protein-based nanotechnology |
| title | Protein-Based Nanoparticle Vaccines for SARS-CoV-2 |
| title_full | Protein-Based Nanoparticle Vaccines for SARS-CoV-2 |
| title_fullStr | Protein-Based Nanoparticle Vaccines for SARS-CoV-2 |
| title_full_unstemmed | Protein-Based Nanoparticle Vaccines for SARS-CoV-2 |
| title_short | Protein-Based Nanoparticle Vaccines for SARS-CoV-2 |
| title_sort | protein based nanoparticle vaccines for sars cov 2 |
| topic | SARS-CoV-2 protein nanoparticles vaccines nanovaccine nanomedicine protein-based nanotechnology |
| url | https://www.mdpi.com/1422-0067/22/24/13445 |
| work_keys_str_mv | AT hyodongsung proteinbasednanoparticlevaccinesforsarscov2 AT nayeonkim proteinbasednanoparticlevaccinesforsarscov2 AT yeramlee proteinbasednanoparticlevaccinesforsarscov2 AT eunjunglee proteinbasednanoparticlevaccinesforsarscov2 |